Recent advances in pharmacokinetic modeling

被引:38
作者
Ahmad, Alaa M. [1 ]
机构
[1] Vertex Pharmaceut Inc, Dept Clin Pharmacol, Cambridge, MA 02139 USA
关键词
pharmacokinetics; mechanistic models; compartmental modeling; population methodologies; ORAL CYCLOSPORINE PHARMACOKINETICS; MEDIATED DRUG DISPOSITION; POPULATION PHARMACOKINETICS; TRANSPLANT RECIPIENTS; PLASMA-CONCENTRATIONS; BAYESIAN-ESTIMATION; HUMAN LIVER; RAT-HEART; ABSORPTION; METABOLITES;
D O I
10.1002/bdd.540
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A major part of the science of pharmacokinetics is the modeling of the underlying processes that contribute to drug disposition. The purpose of pharmacokinetic models is to summarize the knowledge gained in preclinical and clinical studies at various stages in drug development and to rationally guide future studies with the use of adequately predictive models. This review highlights a variety of recent advances in mechanistic pharmacokinetic modeling. It is aimed at a broad audience, and hence, an attempt was made to maintain a balance between technical information and practical applications of pharmacokinetic modeling. It is hoped that drug researchers from all disciplines would be able to get a flavor of the function and capacity of pharmacokinetic modelers and their contribution to drug development. While this review is not intended to be a technical reference on modeling approaches, the roles of statistical applications and population methodologies are discussed where appropriate. Copyright (c) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:135 / 143
页数:9
相关论文
共 51 条
[1]  
[Anonymous], HDB ESSENTIAL PHARM
[2]  
BEAL SL, 1982, CRIT REV BIOMED ENG, V8, P195
[3]   Application of a gamma model of absorption to oral cyclosporin [J].
Debord, J ;
Risco, E ;
Harel, M ;
Le Meur, Y ;
Büchler, M ;
Lachâtre, G ;
Le Guellec, C .
CLINICAL PHARMACOKINETICS, 2001, 40 (05) :375-382
[4]  
Emura T, 2004, INT J MOL MED, V13, P249
[5]   A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe [J].
Ezzet, F ;
Krishna, G ;
Wexler, DB ;
Statkevich, P ;
Kosoglou, T ;
Batra, VK .
CLINICAL THERAPEUTICS, 2001, 23 (06) :871-885
[6]   Integrated pharmacokinetic/pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteers [J].
Fossler, MJ ;
Ebling, WF ;
Ma, S ;
Kornhauser, D ;
Mondick, J ;
Barrett, JS ;
Garner, D ;
Quon, CY ;
Pieniaszek, HJ .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (12) :1326-1334
[7]   Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides [J].
Fukushima, M ;
Suzuki, N ;
Emura, T ;
Yano, S ;
Kazuno, H ;
Tada, Y ;
Yamada, Y ;
Asao, T .
BIOCHEMICAL PHARMACOLOGY, 2000, 59 (10) :1227-1236
[8]   HYBRID PHARMACOKINETIC MODELS TO DESCRIBE ANTI-HIV NUCLEOSIDE BRAIN DISPOSITION FOLLOWING PARENT AND PRODRUG ADMINISTRATION IN MICE [J].
GALLO, JM ;
ETSE, JT ;
DOSHI, KJ ;
BOUDINOT, FD ;
CHU, CK .
PHARMACEUTICAL RESEARCH, 1991, 8 (02) :247-253
[9]   Pharmacokinetic model-predicted anticancer drug concentrations in human tumors [J].
Gallo, JM ;
Vicini, P ;
Orlansky, A ;
Li, SL ;
Zhou, F ;
Ma, JG ;
Puffer, S ;
Bookman, MA ;
Guo, P .
CLINICAL CANCER RESEARCH, 2004, 10 (23) :8048-8058
[10]  
Gibaldi M., 1982, PHARMACOKINETICS, V2, DOI 10.1201/b14095